Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) is one of the first monogenic autoinflammatory diseases to be described [1]. TRAPS is a dominant disease due to mutations in the TNFRSF1A gene and affects patients from all regions of the world [2]. The main clinical features are prolonged recurrent inflammatory flares associated with fever, abdominal pain, myalgia and oedema. Most patients have a germline mutation, but 4 patients with somatic (i.e. post-zygotic) mutations have been described [3–6].
